Why GW Pharmaceuticals Dropped 14% in September

Lackluster trial results for its marijuana medicine for schizophrenia contributed to shares falling last month.

Todd Campbell
Todd Campbell
Oct 8, 2015 at 7:40AM
Health Care

A wave of excitement over using marijuana medically to alleviate symptoms associated with a variety of disease had GW Pharmaceuticals (NASDAQ:GWPH) rewarding investors with significant returns in 2014. However, recent stumbles in the company's pipeline have weighed on shares lately.

In the wake of news last month showing that its marijuana drug cannibidiol for the treatment of schizophrenia posted mixed results, investors knocked shares down by 14%. In the following slideshow, I offer up insight into GW Pharmaceuticals' hopes for marijuana medicine and what investors will be watching closely over the coming months.